Biologics

From new research to FDA nods, here are six key updates in the spine and orthopedic regenerative medicine space since Sept. 1.

Amphix Bio earned FDA breakthrough device designation for a bone regeneration drug-device combination, according to an Oct. 3 news release.

Medical technology company Enovis is partnering with Ossium Health to distribute viable bone matrix allografts.

McAllen, Texas-based Altus Spine and Joint Pain Center partnered with Regenexx to provide noninvasive regenerative medicine services for orthopedic patients. 

Rion, a regenerative medicine company, named five leaders to its advisory board, according to a Sept. 25 news release.

Zetagen Therapeutics' ZetaFuse has potential to treat degenerative disc disease in patients with late-stage cancer, according to a case study in the Journal of the American Academy of Orthopaedic Surgeons.

Cerapedics earned FDA approval to expand the use of its spinal fusion biologic, i-Factor P-15, according to a Sept. 24 news release.

Here are five companies making spine and orthopedic biologic products:

Bone marrow aspirate injections didn't lead to significant changes for patients who had  arthroscopic partial meniscectomy, according to a Sept. 15 study in The American Journal of Sports Medicine.

Spine biologics is a realm ripe for exploration of its potential and applications in patient care.